Whereas in a study of 240 patients with early-stage HER2-positive breast cancer treated with adjuvant trastuzumab-based therapy, PIK3CA mutation-positive breast cancer was associated with significantly poorer OS. Here, ERBB2 is linked to breast carcinoma.